Delaware Investments Delaware Investments Delaware Investments
Print Banner

Print commentary

View printable commentary E-mail this page

This commentary is currently not available. Please check back later.

Delaware Healthcare Fund Quarterly commentary December 31, 2016

Within the Fund

Healthcare stocks fell during the fourth quarter of 2016. The largest driver of performance was the presidential election in the United States, which resulted in a surprise victory for Donald Trump. The early November election triggered a rise in U.S. bond yields, appreciation of the dollar, and a rally in the U.S. stock market. Healthcare stocks have languished, however, due to increasing concerns over pricing power for drugs and proposed reforms to the Affordable Care Act.

During the fourth quarter, Delaware Healthcare Fund (Institutional Class shares and Class A shares at net asset value) slightly underperformed its benchmark, the Russell 3000® Healthcare Index.

Among sectors, the Fund’s holdings in small- and mid-cap medical products contributed the most to relative performance. Both our underweight stance and stock selection were positive. The Fund’s large overweight position in MorphoSys outperformed. MorphoSys remains one of the few antibody technology platforms that has not been acquired by a large pharmaceutical company. The shares have recovered recently due to progress on the company’s pipeline of new products. Additionally, the Fund’s underweight positions in Illumina and Allergan were positive in terms of asset allocation as both of these companies underperformed in the fourth quarter.

Among stocks, the Fund’s overweight position in Sanofi contributed to performance as shares recovered after they were oversold last quarter. Additionally, the Fund’s positions in both Fannie Mae and Freddie Mac rose sharply as the market viewed Trump’s election as a positive for shareholders and increased the likelihood that both companies will be returned to private ownership.

On the negative side, the Fund’s holdings in the biotechnology and blue chip medical products sectors detracted the most from relative performance. In the biotechnology sector, shares of Neurocrine Biosciences sold off while Alder Biopharmaceuticals underperformed due to concerns over patents on its leading products.

In the blue chip medical products sector, the Fund’s overweight position in Chugai Pharmaceutical detracted from performance after the stock sold off following a strong run-up. Additionally, the Fund’s underweight positioning in Celgene and Johnson & Johnson was negative in terms of asset allocation.

Other stocks that detracted from performance included Chinese Internet companies and SINA. SINA succumbed to profit-taking following a strong rally. We believe the company remains well positioned for long-term growth in online advertising. Shares of declined after the company disclosed further losses and funding requirements in its online video business. Despite these concerns, we believe that the company’s overall portfolio of assets, particularly its search business, is undervalued.


For global healthcare investors, there are risks that short-term legislative and judicial action may overshadow the positive long-term fundamentals of the sector and of specific companies. Nevertheless, we continue to see tremendous long-term opportunities in the global healthcare asset class. The baby-boom generation in America is aging, implying expanding demand for healthcare products and services for decades to come. At the same time, middle classes in countries with emerging economies (notably India and China) are growing rapidly, creating big appetites for Western-style medicine. We remain positive on the sector and its growth opportunities.

Looking ahead, we believe that healthcare remains one of the few growth sectors in the economy. With Trump’s presidential victory and Republicans in control of Congress, in our view, there will likely be changes to or a repeal of the Affordable Care Act at some point in the future. We believe this deregulation will be seen by the market as a positive for the healthcare sector.

We believe that the healthcare sector underperformed in 2016 due to cyclical rotation. Healthcare stocks, particularly biotechnology companies, have now corrected and repriced after enjoying a bull run that took place well before the rest of the U.S. market began to recover. We believe the correction in healthcare stocks is now largely done and we continue to see many attractive opportunities.

We continue putting a premium on disciplined, intensive research when analyzing investment opportunities for the Fund. We favor companies that exhibit such traits as:

  • Proven competitiveness
  • Seasoned management teams
  • Stock valuations that are discounted meaningfully from our estimates of intrinsic value.

These characteristics are part of our daily considerations as we follow our conservative, stock-by-stock approach to portfolio management.


The views expressed represent the Manager's assessment of the Fund and market environment as of the date indicated, and should not be considered a recommendation to buy, hold, or sell any security, and should not be relied on as research or investment advice. Information is as of the date indicated and subject to change.

Document must be used in its entirety.


The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance quoted.

Performance data current to the most recent month end may be obtained by calling 800 523-1918 or visiting

Total returns may reflect waivers and/or expense reimbursements by the manager and/or distributor for some or all of the periods shown. Performance would have been lower without such waivers and reimbursements.

Average annual total return as of quarter-end (03/31/2017)
YTD1 year3 year5 year10 yearLifetimeInception
Class A (NAV)9.72%9.72%12.30%8.43%15.65%n/a16.35%09/28/2007
Class A (at offer)3.39%3.39%5.81%6.31%14.29%n/a15.62%
Institutional Class shares9.80%9.80%12.53%8.70%15.95%n/a16.56%09/28/2007
Russell 3000 Healthcare Index8.90%8.90%13.25%10.16%16.95%n/a10.79%

Returns for less than one year are not annualized.

Class A shares have a maximum up-front sales charge of 5.75% and are subject to an annual distribution fee.

Prior to Jan. 28, 2010, the Fund had not engaged in a broad distribution effort of its shares and had been subject to limited redemption requests. The returns reflect expense limitations that were in effect during certain periods and which may have been lower than the Fund's current expenses. The returns would have been lower without expense limitations.

Index performance returns do not reflect any management fees, transaction costs, or expenses. Indices are unmanaged and one cannot invest directly in an index.

Russell 3000® Healthcare Index (view definition)

Expense ratio
Class A (Gross)1.35%
Class A (Net)1.35%
Institutional Class shares (Gross)1.10%
Institutional Class shares (Net)1.10%
Share class ticker symbols
Institutional ClassDLHIX
Top 10 equity holdings as of 04/30/2017
Holdings are as of the date indicated and subject to change.
List excludes cash and cash equivalents.
Holdings based by issuer.
Holding% of portfolio
MorphoSys AG6.7%
Chugai Pharmaceutical Co Ltd5.9%
Eli Lilly & Co5.7%
Amgen Inc5.1%
Perrigo Co PLC4.9%
Pfizer Inc4.0%
GlaxoSmithKline PLC3.7%
Boston Scientific Corp3.6% Inc3.0%
Total % Portfolio in Top 10 holdings51.9%

Institutional Class shares are only available to certain investors. See the prospectus for more information. 

All third-party marks cited are the property of their respective owners.

Russell Investment Group is the source and owner of the trademarks, service marks, and copyrights related to the Russell Indexes. Russell® is a trademark of Russell Investment Group.

Carefully consider the Fund’s investment objectives, risk factors, charges, and expenses before investing. This and other information can be found in the Fund’s prospectus and its summary prospectus, which may be obtained by clicking the prospectus link located in the right-hand sidebar or calling 800 523-1918. Investors should read the prospectus and the summary prospectus carefully before investing.

Investing involves risk, including the possible loss of principal.

Narrowly focused investments may exhibit higher volatility than investments in multiple industry sectors.

Healthcare companies are subject to extensive government regulation and their profitability can be affected by restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure, and malpractice or other litigation.

International investments entail risks not ordinarily associated with US investments including fluctuation in currency values, differences in accounting principles, or economic or political instability in other nations.

Investing in emerging markets can be riskier than investing in established foreign markets due to increased volatility and lower trading volume.

Investments in small and/or medium-sized companies typically exhibit greater risk and higher volatility than larger, more established companies.

“Nondiversified” funds may allocate more of their net assets to investments in single securities than “diversified” funds. Resulting adverse effects may subject these funds to greater risks and volatility.

Not FDIC Insured | No Bank Guarantee | May Lose Value